NRX Pharmaceuticals

NRx Pharmaceuticals' training and monitoring methodology for NRX-101 clinical trials achieved higher interrater reliability on the MADRS depression scale, published in the American Journal of Clinical Psychopharmacology, with implications for future drug approval trials.

NRx Pharmaceuticals' methodology for training and monitoring raters in clinical trials of NRX-101 achieved higher interrater reliability on the MADRS depression scale, published in the American Journal of Clinical Psychopharmacology, with implications for future registration trials and reduced participant numbers needed for statistical significance.

NRx Pharmaceuticals plans to file NDAs for NRX-100 (IV Ketamine) and NRX-101 (Oral D-Cycloserine/Lurasidone) by year-end 2024, targeting suicidal ideation in depression and bipolar depression with suicidality or akathisia. HOPE Therapeutics aims to acquire Interventional Psychiatry Clinics to build a best-in-class network for suicide prevention, expecting first revenue by year-end 2024. The company forecasts profitability in 2025.

NRx Pharmaceuticals to release Q3 and YTD 2024 financial results on Nov 14, 2024, followed by a conference call at 4:30pm ET.

HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals, signs LOI to acquire revenue-generating, EBITDA-positive Interventional Psychiatry Clinics in Florida, expected to be immediately accretive to both revenue and EBITDA.

DelveInsight's 'Bipolar Disorder (Manic Depression) Pipeline Insight, 2024' report details 22+ pipeline drugs from 22+ companies, segmented by RoA, MoA, and molecule types, with therapies in various clinical stages, including late-stage candidates like Vanda Pharmaceuticals' Iloperidone.

NRx Pharmaceuticals and HOPE Therapeutics to present at ThinkEquity Conference on Oct 30, 2024, in New York, featuring Jonathan Javitt, MD, MPH, and NRx management team.